Establishment Labs (NASDAQ:ESTA) Shares Cross Above 50 Day Moving Average – Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $66.26 and traded as high as $67.98. Establishment Labs shares last traded at $67.02, with a volume of 321,678 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ESTA. Mizuho lifted their target price on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Stifel Nicolaus began coverage on shares of Establishment Labs in a research note on Wednesday, October 14th. They issued a “buy” rating and a $85.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, September 21st. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target on the stock in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a report on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.00.

Establishment Labs Stock Up 4.0%

The firm has a market cap of $2.00 billion, a PE ratio of -52.36 and a beta of 1.03. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. The stock has a 50-day simple moving average of $66.26 and a two-hundred day simple moving average of $72.30.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Friday, October 30th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). The company had revenue of $71.99 million for the quarter, compared to the consensus estimate of $66.81 million. Establishment Labs had a negative net margin of 14.56% and a negative return on equity of 185.60%. The company’s quarterly revenue was up 33.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.38) EPS. Analysts expect that Establishment Labs Holdings Inc. will post -1.18 earnings per share for the current year.

Institutional Trading of Establishment Labs

Several large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Establishment Labs during the second quarter worth about $135,752,000. William Blair Investment Management LLC acquired a new stake in Establishment Labs during the second quarter worth about $61,273,000. Bank of America Corp DE acquired a new position in Establishment Labs in the 2nd quarter valued at about $52,176,000. Rice Hall James & Associates LLC acquired a new position in Establishment Labs in the second quarter valued at approximately $48,134,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Establishment Labs in the 2nd quarter worth approximately $28,817,572. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.